Update on bazedoxifene: A novel selective estrogen receptor modulator

References

• AndersonGLLimacherMAssafAR2004Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trialJAMA29117011215082697
   PubMed Web of Science ®Google Scholar
• Barrett-ConnorEMoscaLCollinsP2006Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal womenN Engl J Med3551253616837676
   PubMed Web of Science ®Google Scholar
• BiskobingDM2003Novel therapies for osteoporosisExpert Opin Investig Drugs12611621
   PubMed Web of Science ®Google Scholar
• BlackDMCummingsSRKarpfDB1996Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesLancet3481535418950879
   PubMed Web of Science ®Google Scholar
• BlackDMThompsonDE1999The effect of alendronate therapy on osteoporotic fracture in the vertebral fracture arm of the Fracture Intervention TrialInt J Clin Pract Suppl101465012669740
   PubMedGoogle Scholar
• BlockJEStubbsH1997Hip fracture-associated mortality reconsideredCalcif Tissue Int61849192520
   PubMed Web of Science ®Google Scholar
• BoudesPRonkinSKornerP2003Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast painOsteoporos Intl14S14
   Web of Science ®Google Scholar
• ChandrasekaranAErmerJMcKeandW2003Bazedoxifene acetate metabolic disposition in healthy postmenopausal womenClin Pharmacol Ther7347
   Web of Science ®Google Scholar
• ChestnutCHIIISilvermanSAndrianoK2000A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures studyAm J Med1092677610996576
   PubMed Web of Science ®Google Scholar
• ChestnutCHIIISkagAChristiansenC2004Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosisJ Bone Miner Res191241915231010
   PubMed Web of Science ®Google Scholar
• ChrischillesEAButlerCDDavisCS1991A model of lifetime osteoporosis impactArch Intern Med1512026321929691
   PubMed Web of Science ®Google Scholar
• CummingsSRBlackDMThompsonDE1998Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention TrialJAMA2802077829875874
   PubMed Web of Science ®Google Scholar
• DelmasPDEnsrudKEAdachiJD2002Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trialJ Clin Endocrinol Metab8736091712161484
   PubMed Web of Science ®Google Scholar
• DelmasPDReckerRRChestnutCHIII2004Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE studyOsteoporos Int15792815071723
   PubMed Web of Science ®Google Scholar
• EpsteinS2006Update of current therapeutic options for the treatment of postmenopausal osteoporosisClin Therapeut2815173
   PubMed Web of Science ®Google Scholar
• ErmerJMcKeandWSullivanP2003Bazedoxifene acetate dose proportionality in healthy postmenopausal womenClin Pharmacol Ther7346
   Web of Science ®Google Scholar
• GruberCGruberD2004BazedoxifeneCurr Opin Investig Drugs5108693
   PubMedGoogle Scholar
• HarrisSTWattsNBGenantHK1999Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trialJAMA28213445210527181
   PubMed Web of Science ®Google Scholar
• HendersonNKWhiteCPEismanJA1998The roles of exercise and fall risk reduction in the prevention of osteoporosisEndocrinol Metab Clin North Am27369879669143
   PubMed Web of Science ®Google Scholar
• KharodeYPGreenPDMilliganCL2005Skeletal effects of bazedoxifene acetate (BZA) in ovariectomized mice and comparison of BZA’s effects with raloxifene and lasofoxifene in intact miceJ Bone Mineral Res20S1S406
   Web of Science ®Google Scholar
• KommBSKharodeYPBodinePVN2003aBazedoxifene+conjugated estrogens: a balanced combination to provide optimal “estrogenic”safety and efficacyJ Bone Mineral Res18S2:S272
   Web of Science ®Google Scholar
• KommBSKharodeYPBodinePVN2003bCombining a SERM with conjugated estrogen (CE) to improve the SERM profile: not all SERMs may succeedJ Bone Mineral Res18S2:S273
   Web of Science ®Google Scholar
• KommBSKharodeYPBodinePVN2005Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivityEndocrinology1463999400815961563
   PubMed Web of Science ®Google Scholar
• LibermanUAWeissSRBrollJ1995Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosisN Engl J Med3331437437477143
   PubMed Web of Science ®Google Scholar
• LingXJianliLJingfangL2003Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on biochemical markers of bone metabolism in a Chinese populationOsteoporos Intl14S978
   Web of Science ®Google Scholar
• McClungMRSpencerK1996Nonpharmacologic therapy for osteoporosisRosenCJOsteoporosis:diagnostic and therapeutic principlesTotowa, NJHumana Press18999
   Google Scholar
• McClungMRGeusensPMillerPD2001Effect of risedronate on the risk of hip fracture in elderly womenN Engl J Med3443334011172164
   PubMed Web of Science ®Google Scholar
• MillerCPColliniMDTranBD2001Design, synthesis, and preclinical characterization of novel, highly selective indole estrogensJ Med Chem441654711356100
   PubMed Web of Science ®Google Scholar
• MyersAHRobinsonEGVan NattaML1991Hip fractures among the elderly: factors associated with in-hospital mortalityAm J Epidemiol1341128371746523
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation2006 at http://www.nof.org/osteoporosis/diseasefacts.htm
   Google Scholar
• NeerRMArnaudCDZanchettaJR2001Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopauasal women with osteoporosisN Engl J Med34414344111346808
   PubMed Web of Science ®Google Scholar
• PatatAMcKeandWBaird-BellaireS2003Absolute/relative bioavailability of bazedoxifene acetate in health postmenopausal womenClin Pharmacol Ther7343
   Web of Science ®Google Scholar
• ReginsterJMinneHWSorensenOH2000Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosisOsteoporos Int11839110663363
   PubMed Web of Science ®Google Scholar
• RonkinSClarkeLBoudesP2001TSE-424, a novel tissue selective estrogen, recudes biochemical indices of bone metabolism in a dose related fashionJ Bone Mineral Res16S1:S413
   Web of Science ®Google Scholar
• RonkinSNorthingtonRBaracatE2005Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal womenObstet Gynecol1051397140415932835
   PubMed Web of Science ®Google Scholar
• RossouwJEAndersonGLPrenticeRL2002Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trialJAMA2883213312117397
   PubMed Web of Science ®Google Scholar
• SchurchMARizzoliRMermillodB1996A prospective study on socioeconomic aspects of fracture of the proximal femurJ Bone Miner Res111935428970896
   PubMed Web of Science ®Google Scholar
• SmithSYMinckDJoletteJ2005Bazedoxifene prevents ovariectomy-induced bone loss in the cynomolgus monkeyJ Bone Mineral Res20S1:S174.
   Web of Science ®Google Scholar